好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Prognostic value of early MRI follow-up for no evidence of disease activity (NEDA) after an initial diagnosis of acute disseminated encephalomyelitis (ADEM).
Multiple Sclerosis
P4 - (-)
385
Authors/Disclosures
Diederik L. Koelman
PRESENTER
No disclosure on file
Joshua P. Klein, MD, PhD, FANA, FAAN (Brigham and Women's Hospital) Dr. Klein has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for SAGE Publishers. Dr. Klein has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for McGraw-Hill Publishers. Dr. Klein has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Oakstone Publishers. Dr. Klein has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Wolters Kluwer Publishers. Dr. Klein has received personal compensation in the range of $100,000-$499,999 for serving as an Expert Witness for various law firms. Dr. Klein has received publishing royalties from a publication relating to health care.
No disclosure on file
Farrah J. Mateen, MD, PhD, FAAN (Northwestern University Department of Neurology) Dr. Mateen has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Mateen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Mateen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Dr. Mateen has received research support from Genentech. The institution of Dr. Mateen has received research support from Amgen. The institution of Dr. Mateen has received research support from TG Therapeutics. Dr. Mateen has received intellectual property interests from a discovery or technology relating to health care.